December 27, 2014 1:42 PM ET

Pharmaceuticals

Company Overview of Sigma-Tau Pharmaceuticals, Inc.

Company Overview

Sigma-Tau Pharmaceuticals, Inc., a research-based pharmaceutical company, focuses on the discovery, development, and commercialization of molecules and therapies to help improve the lives of people who suffer from rare diseases. The company offers prescription pharmaceuticals for rare diseases that include tablets, oral solutions, sugar-free oral solutions, and injections; and capsules. It also offers nonprescription medicines and dietary supplements that help to support the normal functions of body. In addition, the company provides third party manufacturing services for customers in the United States, Canada, Mexico, Brazil, Europe, the Middle East, and Africa. Its products cover areas, su...

9841 Washingtonian Boulevard

Suite 500

Gaithersburg, MD 20878

United States

Founded in 1980

Phone:

301-948-1041

Fax:

301-948-1862

Key Executives for Sigma-Tau Pharmaceuticals, Inc.

Chief Executive Officer
Senior Director of Finance
Chief Executive Officer of Sigma-Tau Group
Vice President of Medical Affairs
Vice President of Clinical Affairs
Age: 58
Compensation as of Fiscal Year 2014.

Sigma-Tau Pharmaceuticals, Inc. Key Developments

Sigma-Tau Pharmaceuticals Names Dave Lemus as Chief Executive

Sigma-Tau Pharmaceuticals appointed Dave Lemus as chief executive.

Sigma-Tau Pharmaceuticals, Inc. Signs License Agreement with Crosscare Limited

Sigma-Tau Pharmaceuticals, Inc. announced that it has signed an exclusive United States license agreement with Crosscare Limited to market and distribute Colief Infant Drops for the treatment of colic. Under the multi-year license agreement, Sigma-Tau will be responsible for the sales, marketing and distribution of Colief in the United States.

Sigma-Tau Pharmaceuticals, Inc. Announces Availability of CYSTARAN(TM) 0.44%

Sigma-Tau Pharmaceuticals, Inc. announced the availability of CYSTARAN(TM) (cysteamine ophthalmic solution) 0.44%, the first and only FDA-approved therapy for the treatment of corneal cystine crystal accumulation in patients with cystinosis. Sigma-Tau developed CYSTARAN in partnership with the National Institutes of Health (NIH) and in cooperation with the Cystinosis Foundation, the Cystinosis Research Foundation, and the Cystinosis Research Network. The U.S. Food and Drug Administration (FDA) approved CYSTARAN in October 2012, and the product has also been granted Orphan Drug status. CYSTARAN is available as a sterile ophthalmic solution containing 6.5 mg/mL of cysteamine hydrochloride equivalent to 4.4 mg/mL of cysteamine (0.44%).

Similar Private Companies By Industry

Company Name Region
Kineta One, LLC United States
Silarus Therapeutics, Inc. United States
Biopharmgen Holdings, Inc. United States
Sierra BioSource, Inc. United States
Health & Nutrition Systems International, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sigma-Tau Pharmaceuticals, Inc., please visit www.sigmatau.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.